Ribomic Inc.

4591

JP3974850004

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 11:30:00 17/07/2024 am IST			5-day change	1st Jan Change
93 ^JPY	+2.20%		+2.20%	-13.89%

07/03	Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI
20/02	Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI

Ribomic Inc. announced that it has received ¥17.7 million in funding from SMBC Nikko Securities Inc.

January 27, 2020

On January 27, 2020, Ribomic Inc. (TSE:4591) has closed the transaction. The warrant exercise period from January 28, 2020 to January 27, 2023.

Latest news about Ribomic Inc.

Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	07/03	CI
Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	20/02	CI
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	13/02	CI
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research	17/01	MT
Ribomic Enters Into Drug Research Collaboration with Ajinomoto	17/01	MT
RIBOMIC Inc. and Ajinomoto Co., Inc. Announce Joint Research Agreement	16/01	CI
RIBOMIC Phase I and II Data Published in the Eye	05/12	CI
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13/11	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2024	10/23/10	CI
Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	10/23/10	CI
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/23/12	CI
Ribomic Inc. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	12/23/12	CI
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/23/12	CI
RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan	28/23/28	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	10/23/10	CI
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	10/23/10	CI
Ribomic Signs JV MoU for Development of RBM-007 Aptamer in China; Shares Rise 3%	27/22/27	MT
RIBOMIC Announces MOU to Establish Joint Venture for Development of RBM-007 in China	23/22/23	CI
Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheimer's Trial Death Count Rises to Two	29/22/29	MT
Ribomic Shares Grow 6% as Tokyo Hospital Registers First Case for Achondroplasia Observational Study	29/22/29	MT
Ribomic Inc. Announces the First Case Registration of Observational Study for RBM-007 Early Phase2 Development Project in Achondroplasia Patients	28/22/28	CI
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2022	11/22/11	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	11/22/11	CI
Ribomic Inc. announced that it expects to receive ¥5.1372 million in funding	11/22/11	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	09/22/09	CI

RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
RIBOMIC INC.	-13.89%	2.09Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	13TCr
REGENERON PHARMACEUTICALS, INC.	+23.61%	12TCr
ARGENX SE	+23.26%	2.79TCr
BIONTECH SE	-18.07%	2.1TCr
GENMAB A/S	-15.13%	1.69TCr
BEIGENE, LTD.	-14.81%	1.62TCr
NEUROCRINE BIOSCIENCES, INC.	+9.78%	1.48TCr
WUXI APPTEC CO., LTD.	-46.10%	1.48TCr
SAREPTA THERAPEUTICS, INC.	+52.34%	1.41TCr

Bio Therapeutic Drugs

Ribomic Inc.

Equities

4591

JP3974850004

Biotechnology & Medical Research

Ribomic Inc. announced that it has received ¥17.7 million in funding from SMBC Nikko Securities Inc.

Latest news about Ribomic Inc.

Chart Ribomic Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs